Target gene therapy of glioma: Overexpression of BAX gene under the control of both tissue-specific promoter and hypoxia-inducible element

Acta Biochimica et Biophysica Sinica

Volumn 42, Issue 4, 2010, Pages 274-280

  Huang, Jiwei ^a,b   Gao, Jun ^a   Lv, Xiang ^c   Li, Guilin ^a   Hao, Delong ^c   Yao, Xiaoying ^a   Zhou, Liquan ^c   Liu, Depei ^c   Wang, Renzhi ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Gene therapy; GFAP promoter; Glioma; Hypoxia inducible factor binding site; Musashi1 gene promoter

Indexed keywords

BAX PROTEIN, HUMAN; GLIAL FIBRILLARY ACIDIC PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; PROTEIN BAX;

ANOXIA; APOPTOSIS; ARTICLE; BINDING SITE; BRAIN TUMOR; FLOW CYTOMETRY; GENE THERAPY; GENETICS; GLIOMA; HELA CELL; HUMAN; METABOLISM; METHODOLOGY; PLASMID; PROMOTER REGION; TUMOR CELL LINE;

ANOXIA; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BINDING SITES; BRAIN NEOPLASMS; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE THERAPY; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; PLASMIDS; PROMOTER REGIONS, GENETIC;

EID: 77950581473     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmq016     Document Type: Article

References (19)

1. Central Brain Tumor Registry of the United States (CBTRUS). Statistical report: primary brain tumors in the United States, 1998-2002. CBTRUS, 2006.
2. Germano IM and Binello E. Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside. J Neurooncol 2009, 93: 79-87.
3. Lo HW, Day CP and Hung MC. Cancer-specific gene therapy. Adv Genet 2005, 54: 235-255.
4. Eng LF, Ghirnikar RS and Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 2000, 25: 1439-1451.
5. Nakano A, Kanemura Y, Mori K, Kodama E, Yamamoto A, Sakamoto H and Nakamura Y, et al. Expression of the neural RNA-binding protein Musashi1 in pediatric brain tumors. Pediatr Neurosurg 2007, 43: 279-284.
6. Toda M, Iizuka Y, Yu W, Imai T, Ikeda E, Yoshida K and Kawase T, et al. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia 2001, 34: 1-7.
7. Ma YH, Mentlein R, Knerlich F, Kruse ML, Mehdorn HM and Held-Feindt J. Expression of stem cell markers in human astrocytomas of different WHO grades. J Neurooncol 2008, 86: 31-45.
8. Seigel GM, Hackam AS, Ganguly A, Mandell LM and Gonzalez-Fernandez F. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis 2007, 13: 823-832.
9. Ye F, Zhou C, Cheng Q, Shen J and Chen H. Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer 2008, 8: 108.
10. Kanai R, Eguchi K, Takahashi M, Goldman S, Okano H, Kawase T and Yazaki T. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer-expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy. J Gene Med 2006, 8: 1329-1340.
11. Andrae J, Bongcam-Rudloff E, Hansson I, Lendahl U, Westermark B and Nistér M. A 1.8 kb GFAP-promoter fragment is active in specific regions of the embryonic CNS. Mech Dev 2001, 107: 181-185.
12. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA and Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 1994, 29: 427-431. (Pubitemid 24187904)
13. Kaluz S, Kaluzová M and Stanbridge EJ. Rational design of minimal hypoxiainducible enhancers. Biochem Biophys Res Commun 2008, 370: 613-618.
14. Gu J, Zhang L, Huang X, Lin T, Yin M, Xu K and Ji L, et al. A novel single tetracycline-regulative adenoviral vector for tumor-specific BAX gene expression and cell killing in vitro and in vivo. Oncogene 2002, 21: 4757-4764.
15. Oltvai ZN, Milliman CL and Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, BAX, that accelerates programmed cell death. Cell 1993, 74: 609-619.
16. Seo E, Kim S and Jho EH. Induction of cancer cell-specific death via MMP2 promoter dependent BAX expression. BMB Rep 2009, 42: 217-222.
17. Komata T, Kondo Y, Kanzawa T, Ito H, Hirohata S, Koga S and Sumiyoshi H, et al. Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum Gene Ther 2002, 13: 1015-1025.
18. Ulasov IV, Tyler MA, Zhu ZB, Han Y, He TC and Lesniak MS. Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. Int J Oncol 2009, 34: 729-742.
19. Horst M, Brouwer E, Verwijnen S, Rodijk M, de Jong M, Hoeben R and de Leeuw B, et al. Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP)-selective oncolytic adenovirus. J Gene Med 2007, 9: 1071-1079.